Impact of prior use of topical hemostatic agents on trial of labor after cesarean : Insights from a multicenter cohort study
© 2023 International Federation of Gynecology and Obstetrics..
OBJECTIVE: To evaluate the association between a topical hemostatic agent used at the time of cesarean delivery and uterine scar disruption (rupture or dehiscence) at the subsequent trial of labor after cesarean (TOLAC).
METHODS: A multicenter retrospective cohort study was conducted (2005-2021). Parturients with a singleton pregnancy in whom a topical hemostatic agent was placed during the primary cesarean delivery were compared with patients in whom no such agent was placed. We assessed the uterine scar disruption rate after the subsequent TOLAC and the rate of adverse maternal outcomes. Univariate analyses were followed by multivariate analysis (adjusted odds ratio [aOR]; 95% confidence interval [CI]).
RESULTS: During the study period, 7199 women underwent a trial of labor and were eligible for the study; 430 (6.0%) had prior use of a hemostatic agent, 6769 (94.0%) did not. In univariate analysis, a history of topical hemostatic agent use was not found to be significantly associated with uterine scar rupture, dehiscence, or failed trial of labor. This was also confirmed on multivariate analysis for uterine rupture (aOR 1.91, 95% CI 0.66-5.54; P = 0.23), dehiscence of uterine scar (aOR 1.62, 95% CI 0.56-4.68; P = 0.37), and TOLAC failure (aOR 1.08, 95% CI 0.79-1.48; P = 0.61).
CONCLUSION: A history of hemostatic agent use is not associated with an increased risk for uterine scar disruption after subsequent TOLAC. Further prospective studies in other settings are needed to strengthen these findings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:165 |
|---|---|
| Enthalten in: |
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics - 165(2024), 1 vom: 25. März, Seite 203-210 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Levy, Romi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cesarean delivery |
|---|
| Anmerkungen: |
Date Completed 18.03.2024 Date Revised 18.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/ijgo.15089 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361735324 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361735324 | ||
| 003 | DE-627 | ||
| 005 | 20240318233704.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ijgo.15089 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1334.xml |
| 035 | |a (DE-627)NLM361735324 | ||
| 035 | |a (NLM)37675895 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Levy, Romi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of prior use of topical hemostatic agents on trial of labor after cesarean |b Insights from a multicenter cohort study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.03.2024 | ||
| 500 | |a Date Revised 18.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 International Federation of Gynecology and Obstetrics. | ||
| 520 | |a OBJECTIVE: To evaluate the association between a topical hemostatic agent used at the time of cesarean delivery and uterine scar disruption (rupture or dehiscence) at the subsequent trial of labor after cesarean (TOLAC) | ||
| 520 | |a METHODS: A multicenter retrospective cohort study was conducted (2005-2021). Parturients with a singleton pregnancy in whom a topical hemostatic agent was placed during the primary cesarean delivery were compared with patients in whom no such agent was placed. We assessed the uterine scar disruption rate after the subsequent TOLAC and the rate of adverse maternal outcomes. Univariate analyses were followed by multivariate analysis (adjusted odds ratio [aOR]; 95% confidence interval [CI]) | ||
| 520 | |a RESULTS: During the study period, 7199 women underwent a trial of labor and were eligible for the study; 430 (6.0%) had prior use of a hemostatic agent, 6769 (94.0%) did not. In univariate analysis, a history of topical hemostatic agent use was not found to be significantly associated with uterine scar rupture, dehiscence, or failed trial of labor. This was also confirmed on multivariate analysis for uterine rupture (aOR 1.91, 95% CI 0.66-5.54; P = 0.23), dehiscence of uterine scar (aOR 1.62, 95% CI 0.56-4.68; P = 0.37), and TOLAC failure (aOR 1.08, 95% CI 0.79-1.48; P = 0.61) | ||
| 520 | |a CONCLUSION: A history of hemostatic agent use is not associated with an increased risk for uterine scar disruption after subsequent TOLAC. Further prospective studies in other settings are needed to strengthen these findings | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a VBAC | |
| 650 | 4 | |a cesarean delivery | |
| 650 | 4 | |a maternal morbidity | |
| 650 | 4 | |a topical hemostatic agent | |
| 650 | 4 | |a trial of labor | |
| 650 | 4 | |a uterine rupture | |
| 650 | 4 | |a uterine scar disruption | |
| 700 | 1 | |a Sela, Hen Y |e verfasserin |4 aut | |
| 700 | 1 | |a Weiss, Ari |e verfasserin |4 aut | |
| 700 | 1 | |a Rotem, Reut |e verfasserin |4 aut | |
| 700 | 1 | |a Grisaru-Granovsky, Sorina |e verfasserin |4 aut | |
| 700 | 1 | |a Rottenstreich, Misgav |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics |d 1973 |g 165(2024), 1 vom: 25. März, Seite 203-210 |w (DE-627)NLM000003336 |x 1879-3479 |7 nnns |
| 773 | 1 | 8 | |g volume:165 |g year:2024 |g number:1 |g day:25 |g month:03 |g pages:203-210 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ijgo.15089 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 165 |j 2024 |e 1 |b 25 |c 03 |h 203-210 | ||